News | August 22, 2007

Once Yearly Osteoporosis Treatment FDA Approved

August 23, 2007 — The FDA has approved Reclast (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis.

Approximately 8 million women in the United States suffer from osteoporosis, a disease characterized by low bone mass and reduced bone strength that causes bones to break easily. Osteoporotic fractures are associated with increased morbidity, mortality and healthcare costs.

The approval was based on efficacy and safety data from a three-year study showing that Reclast reduces the frequency of fractures among areas of the body typically affected by osteoporosis, including the hip, spine and non-spine (i.e., hip, wrist, arm, leg, rib). In the trial, Reclast reduced spine fractures by 70 percent and hip fractures by 41 percent.

Reclast belongs to a class of drugs called bisphosphonates, which are used to treat osteoporosis. Research shows that more than half of women on daily or weekly bisphosphonates for postmenopausal osteoporosis will discontinue treatment at the end of one year, potentially leading to a greater risk of fractures. Unlike other bisphosphonate treatments, Reclast is given as a once-yearly 15-minute infusion.

For more information: www.reclast.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
Epsilon Imaging Demonstrates Strain Imaging Integration for Echo Programs at ASE 2018
News | Cardiovascular Ultrasound | June 19, 2018
Clinical practice, along with guidelines and research, have shown that speckle tracking strain imaging can improve...
FDA Clears Bay Labs' EchoMD AutoEF Software for AI Echo Analysis
Technology | Cardiovascular Ultrasound | June 19, 2018
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
How AI and Deep Learning Will Enable Cancer Diagnosis Via Ultrasound

The red outline shows the manually segmented boundary of a carcinoma, while the deep learning-predicted boundaries are shown in blue, green and cyan. Copyright 2018 Kumar et al. under Creative Commons Attribution License.

News | Ultrasound Imaging | June 12, 2018 | Tony Kontzer
June 12, 2018 — Viksit Kumar didn’t know his mother had...
Olympus and Hitachi Healthcare Americas Introduce Arietta 850
News | Ultrasound Imaging | June 04, 2018
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedu
New Ultrasound Guidelines Reliably Identify Children Who Should be Biopsied for Thyroid Cancer

Image courtesy of Loyola Medicine

News | Pediatric Imaging | May 29, 2018
A Loyola Medicine study has found that new ultrasound guidelines can reliably identify pediatric patients who should be...
Samsung Receives FDA Clearance for Premium Ultrasound System RS85
Technology | Ultrasound Imaging | May 07, 2018
NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced the Samsung RS85 ultrasound system has received U....
3D-4D ultrasound of a fetus imaged with a GE Volusion E10 system. It shows the yoke sac. This is a baby ultrasound, also referred to as fetal ultrasound or prenatal ultrasound.

3D-4D ultrasound of a fetus imaged with a GE Volusion E10 system. It shows the yoke sac.

Feature | Ultrasound Women's Health | May 07, 2018
Below is a collection of prenatal ultrasound images from the ITN archive.
Esaote Change of Ownership Completed
News | Ultrasound Imaging | April 30, 2018
The acquisition of biomedical equipment company Esaote SpA’s share capital was completed on April 19, the company...
Overlay Init